Brief: Alpha Cognition Announces Results From Pivotal Study Of Alzheimer's Disease Treatment
22/06/2022 12:15
June 22 (Reuters) - Alpha Cognition Inc ACOG.V :
* ALPHA COGNITION ANNOUNCES POSITIVE RESULTS FROM PIVOTAL
STUDY
WITH ALPHA-1062 IN DEVELOPMENT FOR ALZHEIMER’S DISEASE
* ALPHA COGNITION INC - ALPHA-1062 ACHIEVED BIOEQUIVALENT
AREA-UNDER--CURVE AND PEAK EXPOSURES RELATIVE TO GALANTAMINE
HYDROBROMIDE IR
* ALPHA COGNITION INC - THERE WERE NO ADVERSE EVENTS
REPORTED FOR
ALPHA-1062 DURING STUDIES
* ALPHA COGNITION INC - WITH THESE POSITIVE PIVOTAL STUDY
RESULTS,
ALPHA COGNITION PLANS TO FILE AN NDA FOR ALPHA-1062 IN MILD TO
MODERATE AD IN Q2 2023
Source text for Eikon: ID:nBw74GjPta
Further company coverage: ACOG.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Cognition
See all newsBrief: Alpha Cognition Announces Pricing Of $50 Million Upsized Public Offering And Nasdaq Listing
Brief: Alpha Cognition Inc - Files Registration Statement For $25 Million Offering
Brief: Alpha Cognition Announces Completion Of $4.545 Million Convertible Note And Warrants Bridge Financing
Brief: Alpha Cognition Says On Track To Secure Financing For Continued Growth
Brief: Alpha Cognition Inc Says Applied To List Common Shares On Nasdaq Under Trading Symbol “Acog”